Thermo Fisher Scientific Showcases Innovations for Research and Clinical Labs at AACC 2018

CHICAGO, July 31, 2018 /PRNewswire/ -- AACC -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest innovations for clinical and translational research during the 2018 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo (booth 3831), being held July 29 – August 2 at McCormick Place in Chicago. 

"Clinical customers and translational researchers demand analytical platforms that support higher throughput, accuracy and scalability," said Patrick Durbin, senior vice president and president of specialty diagnostics for Thermo Fisher Scientific. "The common goal is actionable data that's delivered with confidence, and we're highlighting our portfolio of leading products at AACC to support their needs, from research to the clinic."

Comprehensive Laboratory Solutions

With more than one billion samples run on its liquid chromatography – mass spectrometry (LC-MS) systems over the past 10 years, Thermo Fisher is the leader in helping customers analyze complex biological samples rapidly and with greater confidence in the results. The company's LC-MS instruments on display during AACC include:

• The fully automated Thermo Scientific Cascadion SM Clinical Analyzer¹, recently IVD CE-marked in Europe. It is the first all-in-one clinical analyzer with LC-MS/MS technology designed for use by non-experts in a variety of settings. In hospital laboratories, for example, Cascadion will be able to provide results for a range of frequently ordered tests.
• The Thermo Scientific Prelude LX-4 MD HPLC, listed with the FDA as a Class I medical device for general clinical use. The Prelude LX-4 MD quadruples the productivity of a single-channel HPLC by delivering up to four different separations using a single instrument. This results in streamlined LC-MS workflows, reduced idle time and added flexibility for varying clinical separations.
• The Thermo Scientific Endura MD Mass Spectrometer, also a Class I medical device for in vitro diagnostics. This instrument includes triple quadrupole technology for targeted routine analysis where sensitivity, accuracy and ease-of-use in a single platform are paramount. The Endura MD is ideal for clinical labs that require the flexibility to introduce their own laboratory-developed tests.

The Thermo Fisher lab solutions portfolio also includes new instruments for diagnosing allergy and autoimmune conditions. The recently CE-marked Phadia 200¹ instrument requires less than 6 square feet of lab space and can run up to 700 different ImmunoCAP and EliA quantitative tests, including the recently cleared peanut allergen component ImmunoCAP Ara h6.

Finally, Thermo Fisher is proud to showcase the new B·R·A·H·M·S KRYPTOR GOLD¹ immunoassay analyzer. This latest introduction in our B·R·A·H·M·S KRYPTOR line of instruments features increased capacity and has been developed for optimal automation, efficiency and precision.

Consumables to Enhance Performance

Laboratories can minimize interference and maximize instrument uptime with a novel range of ChromaCare flush solutions and ultrapure solvents for ultrahigh-performance LC-MS systems. The ChromaCare consumables can help reduce background noise and prevent protein precipitation while increasing productivity across pharmaceutical, academic, environmental and government laboratories.

Expanded Diagnostic Testing Capabilities

Thermo Fisher will showcase its Ion Torrent Oncomine solutions, including the Oncomine Dx Target Test, the first FDA-approved companion diagnostic for non-small cell lung cancer. Recently, the Centers for Medicare and Medicaid (CMS) announced it would reimburse for the test along with many of the largest commercial health insurers in the U.S. The company will also demonstrate its Ion GeneStudio S5 Prime system, as well as other oncology research assays designed for studies in blood-based cancers, liquid biopsy, childhood cancers and immuno-oncology.

In addition, Thermo Fisher will feature new compounds for antimicrobial susceptibility testing: delafloxacin and meropenem/vaborbactam. The FDA-cleared microbroth dilution plates provide true minimum inhibitory concentration (MIC), facilitating more targeted patient therapy.

Finally, the company's diagnostic testing portfolio continues to expand to meet laboratory demand with the recently announced Thermo Scientific B·R·A·H·M·S PCT direct point-of-care assay. The assay is designed to make procalcitonin (PCT) measurement available to acute care settings where easy handling, quick and precise results are required to support timely clinical decisions.

Increasing Laboratory Sustainability

The new series of Thermo Scientific TSG compact refrigerators has been developed for clinical laboratories and patient care facilities requiring secure and energy-efficient storage of vaccines, medicines, lab kits and breast milk, all in a quiet unit with a small footprint. The new refrigerators have been designed to provide uninterrupted temperature stability and cleanroom-compatible readiness for reliable materials storage. They operate at a sound level of less than 35 dbA and have ENERGY STAR-rated performance, consuming significantly less energy than similar models to meet increasing demands for sustainability and reduced operating costs.

More information on the Thermo Fisher Scientific products and events at AACC 2018 can be found at thermofisher.mediaroom.com/AACC2018.

¹The Cascadion SM Clinical Analyzer, Phadia 200 instrument and B·R·A·H·M·S KRYPTOR GOLD are not for sale in the U.S. and not yet FDA-cleared. Availability of product in each country depends on local regulatory marketing authorization status.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

Media Contact Information:
Charlotte McCormack
Thermo Fisher Scientific
(508) 207-3696
[email protected]

or

Investor Contact Information:
Ken Apicerno
Thermo Fisher Scientific
(781) 622-1294
[email protected]

SOURCE Thermo Fisher Scientific

Related Links

http://www.thermofisher.com